It was demonstrated that NAD+-boosting therapy can upregulate FNDC5/Irisin, resulting in positive outcomes like reduced body weight gain, improved hepatic steatosis, insulin resistance, and decreased mitochondrial dysfunction and fibrosis [103]. Here, FNDC5 is linked to fatty liver disease.